Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
News|Slideshows|December 12, 2022
9 Indicators of Personal Stress and How the 50 States Rank
Author(s)Grace Halsey
From crime rates and credit scores to average health and hours worked in a week, find the 5 states that rank highest and the 5 lowest across 9 composite measures of stress.
Advertisement
Advertisement
Related to this article
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.
The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.
Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.
Advertisement
Advertisement
Trending on Patient Care Online
1
American Cancer Society Updates Prostate Cancer Screening Guidelines
2
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
3
Yoga-Based Cardiac Rehab Improves Quality of Life in Heart Failure Trial
4
Contraindicated Hormone Therapy Prescribing Climbs in Primary Care
5